Abstract

Objective: The study aimed at evaluating the local tumor control, survival data and prognostic factors following treatment with transarterial chemoembolization (TACE) in the palliative therapy of patients with liver metastases from non-small-lung-cancer (NSCLC). Material and methods: The study was retrospectively performed following approval of the ethical committee. 56 patients (mean age, 53.4 years) with liver metastases of NSCLC (Stage IV) undergone repeated TACE. Overall, 214 TACE procedures were administered (mean, 3.8 sessions/patient). The administered chemotherapeutic agents included mitomycin, gemcitabine and cisplatin. For embolization lipiodol and degradable starch microspheres (DSM) were used. Results: The local response of the tumors was assessed by MRI using RECIST 1.1. Patient survival was evaluated using Kaplan-Meier method and compared with the log-rank-test. The local tumor control was: partial response in 14.3%, stable disease in 51.8% and progressive disease in 33.9% of patients. The patients’ survival rate was 59%, 9% and 2% after 1, 2 and 3 years. The median survival time was 11 months. Initial tumor response (p = 0.04) and high tumor vascularity (p = 0.03) were statistically significant factors for patient`s survival. Conclusion: TACE could be used as a therapeutic option for the palliative management of selected patients with hepatic metastases of NSCLC origin with satisfactory local tumor control capability.

Authors and Affiliations